Litcius/Paper detail

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study

Timothy Craig, Donald S. Levy, Avner Reshef, William R. Lumry, Inmaculada Martinez‐Saguer, Joshua Jacobs, William H. Yang, Bruce Ritchie, Emel Aygören‐Pürsün, Paul K. Keith, Paula J. Busse, Henrike Feuersenger, Mihai Alexandru Bica, Iris Jacobs, Ingo Pragst, Markus Magerl

2024The Lancet Haematology19 citationsDOI

Topics & Concepts

MedicineHereditary angioedemaQuality of life (healthcare)AngioedemaOpen labelIntensive care medicineAdverse effectTerm (time)PediatricsInternal medicineDermatologyNursingPhysicsQuantum mechanicsCoagulation, Bradykinin, Polyphosphates, and AngioedemaHemophilia Treatment and ResearchComplement system in diseases
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study | Litcius